India-UK FTA Drives $981M Pharma Export Target, 8.66% Jump by FY27

For biotech and pharma strategists, the India-UK FTA is more than a trade deal: it’s a market-access catalyst. With tariffs eliminated, Indian generic and biosimilar manufacturers gain an immediate cost advantage in Europe’s largest pharma market, unlocking a projected export surge to $981 million by FY27. This shift opens the door to deeper R&D partnerships, clinical trial collaborations, and supply chain integration across the two nations’ life sciences sectors.

India's pharmaceutical export engine is poised for a significant uptick as the India-UK Comprehensive Economic and Trade Agreement (CETA) reshapes bilateral trade dynamics. On July 16, 2026, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) projected that Indian pharma shipments to the United Kingdom will climb 8.66 per cent year-on-year to reach USD 981.16 million in the fiscal year ending March 2027, building on a robust USD 902.96 million recorded in FY2025-26. The zero-tariff provision under the newly implemented FTA lies at the heart of this forecast, effectively eliminating customs duties on virtually all pharmaceutical products and thereby slashing the landed cost of Indian generics in the British market. The announcement underscores a pivotal shift in the Indo-UK commercial relationship, where pharmaceuticals emerge as a cornerstone of a broader strategic partnership.

“

With tariffs eliminated, Indian generic and biosimilar manufacturers gain an immediate cost advantage in Europe’s largest pharma market, unlocking a projected export surge to $981 million by FY27.

The composition of this trade reveals India's deepening integration into the UK's healthcare supply chain. Drug formulations and biologicals already command an overwhelming 89.54 per cent share of total pharma exports, with APIs and bulk drugs contributing USD 72.66 million in FY2025-26 alone. This skew toward finished dosage forms — largely affordable generic versions of off-patent blockbusters — aligns perfectly with the UK National Health Service's perpetual quest for cost containment. The country's status as India's largest pharmaceutical export destination in Europe and third-largest globally, as highlighted by Pharmexcil Chairman Namit Joshi, makes the tariff elimination particularly consequential. A trade surplus of approximately USD 767.49 million in the previous fiscal year further attests to India's competitive advantage in the market.

Early indicators suggest the momentum is already building. In the April-May 2026 window, exports surged 4.15 per cent year-on-year to USD 152.14 million, compared with USD 146.08 million a year earlier. If this trajectory holds, the full-year target may prove conservative. The zero-tariff regime not only boosts price competitiveness but also creates a foundation for deeper industrial collaboration. Pharmexcil Vice Chairman Bhavin Mehta emphasized the strategic value of the UK market, and the council sees the FTA as a catalyst for foreign direct investment, joint manufacturing ventures, and joint R&D initiatives. This moves the narrative beyond pure transactional trade toward a holistic partnership that could elevate India's pharmaceutical sector up the value chain, potentially fostering innovation in biosimilars, complex generics, and novel drug delivery systems.